

Financial Tear Sheet

Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Stock Information

XBIT (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.44
Change (%)	▼ 0.11 (3.10%)
Volume	32,770
52 Week Low	\$2.13
Market Cap	\$127,160,191
Rolling EPS	-0.68
PE Ratio	0
Shares Outstanding	35,819,772
Data as of 10/22/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
10/05/18	XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis
09/26/18	XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases
09/24/18	XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
10/12/18	4
10/04/18	4
10/01/18	4
09/18/18	4

Management

John Simard	Founder, President, Chief Executive Officer & Chairman
Norma I. Gonzalez	Vice President of Quality
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Chief Scientific Officer

Primary IR Contact

James S. Whitehurst
XBiotech
Phone: +1 512.386.2993
Email: swhitehurst@xbiotech.com

Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Thorpe McKenzie	Director
Jan-Paul Waldin	Director
Donald H. MacAdam	Director